摘要
目的探讨丹参酮ⅡA(TanⅡA)对2型糖尿病(T2DM)患者外周血中基质细胞衍生因子-1(SDF-1)和其受体CXCR4的影响。方法62例T2DM患者随机分为对照组和实验组。对照组采用常规治疗;实验组在常规治疗基础上加用TanⅡA40mg.d-1,持续2周。测定治疗前后所有对象的外周血中SDF-1浓度、内皮祖细胞(EPCs)数量及其表面CXCR4阳性率。结果治疗前,两组各项参数比较差异无统计学意义(P>0.05)。治疗前后比较,对照组各参数差异无统学意义(P>0.05)。实验组治疗后较治疗前SDF-1、CXCR4、EPCs上升,差异有统计学意义(P<0.05或P<0.01);且EPCs与SDF-1呈显著性正相关(r=0.223,P<0.05)。结论TanⅡA可升高T2DM患者外周血中SDF-1水平和上调CXCR4的表达,从而增加EPCs数量,改善内皮功能。
AIM To study effect of Tanshinone ⅡA （TanⅡA） on stromal cell-derived factor-1（SDF-1） and it＇s receptors CXCR4 in patients with type 2 diabetes mellitus（T2DM）. METHODS Sixty-two patients with T2DM were randomly divided into treatment and control groups. Tan ⅡA 40 mg·d^-1 was given to patients in treatment group for 2 weeks. The level of plasma SDF-1, the positive rate of CXCR4 on endothelial progenitor cells （EPCs）and the number of EPCs were determined pre- and post- treatment. RESULTS All parameters had no significant differences between 2 groups before observation（ P 〉 0.05）. Increasing SDF-1, EPCs and CXCR4 had significant difference in the treatment group pre- and post- treatment （ P 〈 0.05 or P 〈 0.01 ）. The parameters had no significant differences between before and after observation in the control group （ P 〉 0.05）. There was a significant positive correlation between EPCs and SDF-1 （ r = 0. 223, P 〈 0.05）. CONCLUSION Tan ⅡA can improve vascular endothelial function in T2DM, which may be due to elevating the level of plasma SDF-1 and increasing the expression of CXCR4 on EPCs, and inducing EPCs mobilization from bone marrow to peripheral blood.
出处
《中国临床药学杂志》
CAS
2010年第2期99-102,共4页
Chinese Journal of Clinical Pharmacy
基金
江苏大学临床医学科技发展基金(JLY20080069)
关键词
丹参酮ⅡA
2型糖尿病
基质细胞衍生因子-1
受体
内皮祖细胞
Tanshinone ⅡA
type 2 diabetes mellitus
stromal cell-derived factor-1
receptor
endothelial progenitor cells
